Shire has acquired the worldwide rights excluding US, Canada and Barbados for Equasym® IR and XL from UCB. Equasym, a treatment for attention deficit hyperactivity disorder (ADHD), was divested by UCB because it is not a core product, but it fits in very nicely with Shire’s strategy to enter the European market.